(Portola Hills, CA) Neopharmica, a California corporation has introduced a dietary supplement into the United States that purports to significantly reduce the chances of heart attack in known risk groups. This product, known as HeartHealth, is the subject of several clinical studies and is currently dispensed in over 130 hospitals in Asia. It not only has been shown to reduce risk of heart attack but also can significantly relieve chest pain, palpitations, dizziness, ringing in the ears and shortness of breath in patients with atherosclerosis of the heart. Some 60% of patients have been able to reduce or discontinue their heart medication. About 87% have obtained a generally effective improvement on their EKG profile.

Dr. Stephen Paul, President of Neopharmica and a 26 year veteran of the industry describes what other companies are doing. He explains, "Ever notice what some vitamin ads are saying? They say, their product will: lower cholesterol, increase HDL levels, block fat absorption, improve lipid metabolism, lower homocysteine levels, improve blood circulation, etc. But, what does this all really mean? Will these vitamins make you live longer? Will you feel healthier? Can you reduce or eliminate some of the medicines you are taking? The fundamental issue then is not how vitamins can regulate or change biochemical events in your body. The real bottom line is whether they actually will make you live longer by reducing your chances of first time or recurrent heart attacks. HeartHealth is the first dietary supplement of its kind that has been clinically documented to be effective in risk reduction of heart attack."

Neopharmica is currently negotiating contracts with several firms, for the wholesale distribution of this product.





This article courtesy of <%HOME-URL%>.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.

Submit Your Article